Oramed Announces Last Patient Treated in Pivotal Oral Insulin Trial
Oramed Pharmaceuticals Inc. recently announced the treatment of the last patient in the primary cohort of the Phase 2b HbA1c trial evaluating Oramed’s lead oral insulin candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of Type 2 diabetes.
The Phase 2b double-blind, randomized, 90-day dose-ranging trial will assess the primary efficacy endpoint of reduction in HbA1c, as well as safety endpoints. Topline data from the primary cohort of the Phase 2b trial are expected to be released in the fourth quarter of 2019.
Oramed Chief Executive Officer Nadav Kidron said, “Our lead oral insulin program could be a major advancement for the diabetes community as we believe it should offer a healthier way to treat diabetes. With the last patient out in this pivotal trial, we have positioned ourselves as the leader in the clinical development of oral insulin.”
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology that is based on more than 30 years of research by scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of Type 2 and Type 1 diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901, which has potential to be the first orally-ingestible GLP-1 analog. For more information, please visit www.oramed.com
Total Page Views: 1997
